# EDGAR Filing Document

**Accession Number:** 0001447362
**File Stem:** 0001628280-26-039189
**Filing Date:** 2026-5
**Character Count:** 6444
**Document Hash:** 2b6199ef4ab58ed1a548bfcdc250de48
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-039189.hdr.sgml**: 20260529

**ACCESSION NUMBER**: 0001628280-26-039189

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260528

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260529

**DATE AS OF CHANGE**: 20260529

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CASTLE BIOSCIENCES INC
- **CENTRAL INDEX KEY:** 0001447362
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 770701774
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38984
- **FILM NUMBER:** 261044586

**BUSINESS ADDRESS:**
- **STREET 1:** 1500 W. PARKWOOD AVE.
- **STREET 2:** SUITE 400
- **CITY:** FRIENDSWOOD
- **STATE:** TX
- **ZIP:** 77546
- **BUSINESS PHONE:** 866-788-9007

**MAIL ADDRESS:**
- **STREET 1:** 1500 W. PARKWOOD AVE.
- **STREET 2:** SUITE 400
- **CITY:** FRIENDSWOOD
- **STATE:** TX
- **ZIP:** 77546

?xml version='1.0' encoding='ASCII'? cstl-20260528

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 28, 2026**

**Castle Biosciences, Inc.**

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38984** | **77-0701774** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **1500 W. Parkwood Ave, Suite 400**<br>**Friendswood, Texas** | **77546** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (866) 788-9007**

**Not Applicable**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.001 par value per share** | **CSTL** | **The Nasdaq Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On May 28, 2026, Castle Biosciences, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the following matters and cast their votes as set forth below:

**Proposal 1. Election of Directors**

The Company's stockholders elected the three individuals listed below as Class I Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **For** | **Withhold** | **Broker Non-Votes** |
| Ellen Goldberg | 15,455,265 | 7,118,166 | 2,415,788 |
| Miles D. Harrison | 15,607,369 | 6,966,062 | 2,415,788 |
| Tiffany P. Olson | 14,380,655 | 8,192,776 | 2,415,788 |

---

**Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm**

The Company's stockholders ratified the selection of KPMG LLP by the Audit Committee of the Company's Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 24,531,366 | 445,666 | 12,187 |

---

**Proposal 3. Approval of the Compensation of the Company's Named Executive Officers**

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 8, 2026 (the "Proxy Statement"). The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 21,280,180 | 1,281,394 | 11,857 | 2,415,788 |

---

**Proposal 4. Approval of the Company's Non-Employee Director Compensation Policy**

The Company's stockholders approved the Company's non-employee director compensation policy as described in the Proxy Statement. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 21,394,330 | 1,130,133 | 48,968 | 2,415,788 |

---

------

---

| |
|:---|
| **SIGNATURES** |
| Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. |

---

---

| | | |
|:---|:---|:---|
| | **CASTLE BIOSCIENCES, INC.** | **CASTLE BIOSCIENCES, INC.** |
| | By: | /s/ Derek J. Maetzold |
| | | Derek J. Maetzold |
| | | President and Chief Executive Officer |
| Date: May 29, 2026 |  |  |

---